Systematic review of the role of surgery in the treatment of pancreatic cancer with liver oligometastases

Pancreatic cancer remains one of the most aggressive malignancies with an extremely poor prognosis. Despite advances in systemic therapy five-year survival rates for patients with disseminated forms of the disease still do not exceed a few percent. Surgical treatment for advanced pancreatic cancer is not performed in routine practice and is considered palliative.
However, efforts to introduce surgery for stage IV disease continue to be investigated particularly in patients with oligometastatic disease. This group of patients occupies an intermediate position in terms of tumor biology between localized cancer and disseminated disease, providing a theoretical rationale for the use of radical local treatment modalities in combination with effective systemic therapy.
The aim of this review is to systematize current data regarding the role efficacy and safety of surgical treatment in patients with oligometastatic pancreatic cancer as well as to define the selection criteria for patients most suitable for combined treatment. This work analyzes the results of key studies and discusses prognostic factors that enable the selection of the most appropriate candidates for combined treatment.

1. Nagai M., Wright M.J., Ding D., et al. Oncologic resection of pancreatic cancer with isolated liver metastasis: Favorable outcomes in select patients. J Hepatobiliary Pancreat Sci 2023;30(8):1025–1035. https://doi.org/10.1002/jhbp.1303

2. Hank T., Klaiber U., Hinz U., et al. Oncological outcome of conversion surgery after preoperative chemotherapy for metastatic pancreatic cancer. Ann Surg 2023;277(5):e1089-e1098. https://doi.org/10.1097/SLA.0000000000005481

3. Satoi S., Yamamoto T., Hashimoto D., et al. Oncological role of surgical resection in patients with pancreatic ductal adenocarcinoma with liver-only synchronous metastases in a single-center retrospective study. J Gastrointest Oncol 2023;14(6):2587–2599. https://doi.org/10.21037/jgo-23-655

4. Nakata K., Miyasaka Y., Ishizawa T., et al. Patients with pancreatic cancer with synchronous liver oligometastasis show a significant long-term survival benefit from resection under specific conditions: a multicenter national cohort study. J Hepatobiliary Pancreat Sci 2025 Aug;32(8):611–619. https://doi.org/10.1002/jhbp.12181

5. Bachellier P., Addeo P., Averous G., Dufour P. Resection of pancreatic adenocarcinoma with synchronous liver metastases: a retrospective study of prognostic factors for survival. Surgery 2022;172(4):1245–1250. https://doi.org/10.1016/j.surg.2022.03.003

6. Safi S.A., Fluegen G., Rehders A., et al. Surgical margin clearance and extended chemotherapy defines survival for synchronous oligometastatic liver lesions of the ductal adenocarcinoma of the pancreas. Int J Clin Oncol 2021;26(10):1911–1921. https://doi.org/10.1007/s10147-021-01961-5

7. Shao Y., Feng J., Hu Z., et al. Feasibility of pancreaticoduodenectomy with synchronous liver metastasectomy for oligometastatic pancreatic ductal adenocarcinoma: a case-control study. Ann Med Surg (Lond) 2020;62:490–494. https://doi.org/10.1016/j.amsu.2020.11.037

8. Takeda T., Sasaki T., Okamoto T., et al. Outcomes of pancreatic cancer with liver oligometastasis. J Hepatobiliary Pancreat Sci 2023;30(2):229–239. https://doi.org/10.1002/jhbp.1184

9. Andreou A., Knitter S., Klein F., et al. The role of hepatectomy for synchronous liver metastases from pancreatic adenocarcinoma. Surg Oncol 2018;27(4):688–694. https://doi.org/10.1016/j.suronc.2018.09.004

10. Yang J., Zhang J., Liu W., et al. Patients with hepatic oligometastatic pancreatic body/tail ductal adenocarcinoma may benefit from synchronous resection. HPB (Oxford) 2020;22(1):91–101. https://doi.org/10.1016/j.hpb.2019.05.015

11. Hackert T., Niesen W., Hinz U., et al. Radical surgery of oligometastatic pancreatic cancer. Eur J Surg Oncol 2017;43(2):358–363. https://doi.org/10.1016/j.ejso.2016.10.023

12. Tachezy M., Gebauer F., Janot M., et al. Synchronous resections of hepatic oligometastatic pancreatic cancer: disputing a principle in a time of safe pancreatic operations in a retrospective multicenter analysis. Surgery 2016;160(1):136–144. https://doi.org/10.1016/j.surg.2016.02.019

13. Crippa S., Bittoni A., Sebastiani E., et al. Is there a role for surgical resection in patients with pancreatic cancer with liver metastases responding to chemotherapy? Eur J Surg Oncol 2016;42(10):1533–1539. https://doi.org/10.1016/j.ejso.2016.06.398

14. Leonhardt C.S., Stamm T., Hank T., Prager G., Strobel O. Defining oligometastatic pancreatic cancer: a systematic review and critical synthesis of consensus. ESMO Open 2023;8(6):102067. https://doi.org/10.1016/j.esmoop.2023.102067

15. Hamad A., Underhill J., Ansari A., et al. Surgical treatment of hepatic oligometastatic pancreatic ductal adenocarcinoma: An analysis of the National Cancer Database. Surgery 2022;171(6):1464–1470. https://doi.org/10.1016/j.surg.2021.12.029

16. Yamanaka M., Hayashi M., Yamada S., et al. A possible definition of oligometastasis in pancreatic cancer and associated survival outcomes. Anticancer Res 2021;41(8):3933–3940. https://doi.org/10.21873/anticanres.15189

17. Damanakis A.I., Ostertag L., Waldschmidt D., et al. Proposal for a definition of “Oligometastatic disease in pancreatic cancer”. BMC Cancer 2019;19:1261. https://doi.org/10.1186/s12885-019-6448-9

18. Christodoulidis G., Magouliotis D.E., Samara A.A., et al. The surgical challenge of oligometastatic pancreatic cancer: a systematic review of the literature. J BUON. 2021 Sep-Oct;26(5):1742–1746. PMID: 34761577

19. Frigerio I., Malleo G., de Pastena M., et al. Prognostic factors after pancreatectomy for pancreatic cancer initially metastatic to the liver. Ann Surg Oncol 2022;29(13):8503–8510. https://doi.org/10.1245/s10434-022-12385-4

20. Ji X., Zhao Y., He C., et al. Clinical effects of stereotactic body radiation therapy targeting the primary tumor of liver-only oligometastatic pancreatic cancer. Front Oncol 2021;11:659987. https://doi.org/10.3389/fonc.2021.659987

21. Elhariri A., Patel J., Mahadevia H., et al. Stereotactic body radiation therapy in oligometastatic pancreatic cancer: overall survival improvement and SMAD4 as a predictor of progression-free survival. J Gastrointest Oncol 2025;16(4):1658–1666. https://doi.org/10.21037/jgo-2025-100

22. Jiang L., Ye Y., Feng Z., et al. Stereotactic body radiation therapy for the primary tumor and oligometastases versus the primary tumor alone in patients with metastatic pancreatic cancer. Radiat Oncol 2024;19(1):111. https://doi.org/10.1186/s13014-024-02493-8

23. Scorsetti M., Comito T., Franceschini D., et al. Is there an oligometastatic state in pancreatic cancer? Practical clinical considerations raise the question. Br J Radiol 2020;93(1106):20190627. https://doi.org/10.1259/bjr.20190627

24. Hua Y.Q., Wang P., Zhu X.Y., et al. Radiofrequency ablation for hepatic oligometastatic pancreatic cancer: an analysis of safety and efficacy. Pancreatology 2017;17(6):967–973. https://doi.org/10.1016/j.pan.2017.08.072

25. Lee G., Kim D.W., Oladeru O.T., et al. Liver metastasis-directed ablative radiotherapy in pancreatic cancer offers prolonged time off systemic therapy in selected patients: data from a multi-institutional retrospective study. Pancreas 2021;50(5):736–743. https://doi.org/10.1097/MPA.0000000000001822

26. Elamir A.M., Karalis J.D., Sanford N.N., et al. Ablative radiation therapy in oligometastatic pancreatic cancer to delay polyprogression, limit chemotherapy, and improve outcomes. Int J Radiat Oncol Biol Phys 2022;114(4):792–802. https://doi.org/10.1016/j.ijrobp.2022.07.019

27. Lu W, Wang L, Lou J, Tang K. Sequential therapy for pancreatic cancer patients with synchronous oligo-hepatic metastatic lesions. Tumori. 2023 Jun;109(3):307–313. DOI: 10.1177/03008916221110265. PMID: 35815545.

28. Kandel P., Wallace M.B., Stauffer J., et al. Survival of patients with oligometastatic pancreatic ductal adenocarcinoma treated with combined modality treatment including surgical resection: a pilot study. J Pancreat Cancer 2018;4(1):88–94. https://doi.org/10.1089/pancan.2018.0011

29. D’Ambra V., Ricci C., Ingaldi C., et al. Stage IV pancreatic ductal adenocarcinoma (PDAC) with synchronous liver metastasis: are there survival benefits in liver resection? A systematic review and meta-analysis. Eur J Surg Oncol 2025;51(5):109598. https://doi.org/10.1016/j.ejso.2025.109598

30. Fiorillo C., Langellotti L., Panza E., et al. Surgical treatment of synchronous liver-only oligometastatic pancreatic adenocarcinoma: a systematic review and meta-analysis of long-term outcomes. Int J Surg 2025;111(5):3589–3598. https://doi.org/10.1097/JS9.0000000000002338

31. Conroy T., Desseigne F., Ychou M., et al; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364(19):1817–25. https://doi.org/10.1056/NEJMoa1011923

32. Wainberg Z.A., Melisi D., Macarulla T., et al. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial. Lancet 2023;402(10409):1272–1281. https://doi.org/10.1016/S0140-6736(23)01366-1

33. Schwarz C., Fitschek F., Primavesi F., et al. Metachronous hepatic resection for liver only pancreatic metastases. Surg Oncol 2020;35:169–173. https://doi.org/10.1016/j.suronc.2020.08.005

34. Yun W.G., Kwon W., Han Y., et al. Can surgical resection of metastatic lesions be beneficial to pancreatic ductal adenocarcinoma patients with isolated lung metastasis? Cancers (Basel) 2022;14(9):2067. https://doi.org/10.3390/cancers14092067